Inhibition of RNA immunogenicity by nucleoside base modification paves the way for the success of COVID-19
ZHAI Tian-Tian1, LIU Mo-Fang2, LEI Xin-Hai1,*
1Cancer Stem Cell Research Institute of Dalian Medical University, Dalian 116044, China；2Center of Excellence in Molecular Cell Science, CAS/Shanghai Institute of Biochemistry and Cell Biology, Shanghai 200031, China
The recently announced 2023 Nobel Prize in Physiology/Medicine was awarded to the Hungarian born American biologist Katalin Karik ó and the American biologist Drew Weissman for their breakthrough discovery on nucleoside base modification, thus laying a solid foundation for the development of an efficient novel coronavirus mRNA vaccine. This is also the discovery of polynucleotide phosphorylase (1959 Nobel Prize in Physiology/Medicine), determination of yeast Ala-tRNA sequence (1969 Nobel Prize in Physiology/Medicine), discovery of reverse transcription phenomenon (1975 Nobel Prize in Physiology/Medicine), discovery of intron and RNA splicing phenomena (1993 Nobel Prize in Physiology/Medicine), discovery of ribozyme (1993 Nobel Prize in Chemistry) The discovery of RNA interference phenomenon (Nobel Prize in Physiology/Medicine in 2006), the study of transcription mechanisms in eukaryotic organisms (Nobel Prize in Chemistry in 2006), and CRISPR/Cas9 gene editing technology (Nobel Prize in Chemistry in 2020) are another major scientific discovery in the RNA field that received the Nobel Prize in Physiology/Medicine.
Corresponding author: LEI Xin-Hai E-mail: email@example.com
Citing This Article：
ZHAI Tian-Tian, LIU Mo-Fang, LEI Xin-Hai. Inhibition of RNA immunogenicity by nucleoside base modification paves the way for the success of COVID-19. Acta Physiol Sin 2023; 75 (5): 605-610 (in Chinese with English abstract).